JW Therapeutics (HKEX: 2126), an independent and pioneering biotechnology company, is making strides in the field of cell immunotherapy with the launch of a clinical study of Carteyva®, its revolutionary relmacabtagene autoleucel injection. The groundbreaking drug is being tested for use as a first-line treatment for high-risk large B-cell lymphoma, with the first patient receiving the injection and beginning the trial.
High-risk large B-cell lymphoma, including those with International Prognostic Index (IPI) score ≥3 and high-grade B-cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 translocations (double-/triple-hit lymphomas; DHL/THL), is associated with a poor prognosis and a low response to standard first-line therapies. While traditional standard first-line R-CHOP chemotherapy has a complete response rate (CRR) of 59.6%, DA-EPOCH-R therapy has not been shown to significantly improve survival outcomes. As such, patients with high-risk large B-cell lymphoma face a pressing need for more effective treatment options.
The groundbreaking Carteyva® clinical trial (RELIANCE study) has unveiled an encouraging safety profile and remarkable efficacy in treating relapsed/refractory large B-cell lymphoma patients who have already received two lines of therapies. These incredible results are inspiring the use of CAR-T therapy in earlier lines of therapies for high-risk large B-cell lymphoma.
This exciting investigator-initiated trial (IIT) in China is pushing the boundaries of cancer treatment. It is an open-label, single-arm, multicenter trial, testing the efficacy and safety of Carteyva® as first-line therapy in adult subjects with high-risk large B-cell lymphoma. With the potential to revolutionize the way this type of cancer is treated, the trial is sure to be closely watched.
About Relmacabtagene Autoleucel Injection (trade name: Carteyva®)
Relma-cel, the first CAR-T cell immunotherapy product of JW Therapeutics, has made history as the first biologics product approved by the China National Medical Products Administration (NMPA) for two indications – the treatment of relapsed or refractory large B-cell lymphoma and refractory or relapsed within 24 months of second-line or above systemic treatment of follicular lymphoma. In addition, it is the only CAR-T product in China that has been simultaneously included in the National Significant New Drug Development Program, priority review, and breakthrough therapy designations. This remarkable product is a testament to the technological advancement of CAR-T therapy and its potential to revolutionize the treatment of various kinds of lymphomas.
About JW Therapeutics
At JW Therapeutics (HKEX: 2126), we are dedicated to becoming the innovation leader in cell immunotherapy. Founded in 2016, we have built a world-class platform for product development in cell immunotherapy, as well as a pipeline of products that cover hematologic malignancies, solid tumors, and autoimmune diseases. We are devoted to providing breakthrough and quality cell immunotherapy products to patients in China and worldwide, and to leading the healthy and standardized development of China’s cell immunotherapy industry. With our cutting-edge products, we hope to bring the promise of a cure to those in need.